There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LXEO is 21.63M, and at present, short sellers hold a 2.91% of that float. The average trading volume of LXEO on July 03, 2024 was 156.90K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LXEO) stock’s latest price update
Lexeo Therapeutics Inc. (NASDAQ: LXEO) has experienced a decline in its stock price by -10.19 compared to its previous closing price of 15.61. However, the company has seen a fall of -16.89% in its stock price over the last five trading days. zacks.com reported 2024-05-14 that Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LXEO’s Market Performance
Lexeo Therapeutics Inc. (LXEO) has experienced a -16.89% fall in stock performance for the past week, with a -15.69% drop in the past month, and a -3.97% drop in the past quarter. The volatility ratio for the week is 11.76%, and the volatility levels for the past 30 days are at 8.43% for LXEO. The simple moving average for the past 20 days is -16.42% for LXEO’s stock, with a -2.94% simple moving average for the past 200 days.
Analysts’ Opinion of LXEO
Many brokerage firms have already submitted their reports for LXEO stocks, with Robert W. Baird repeating the rating for LXEO by listing it as a “Outperform.” The predicted price for LXEO in the upcoming period, according to Robert W. Baird is $28 based on the research report published on June 13, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXEO reach a price target of $22. The rating they have provided for LXEO stocks is “Buy” according to the report published on June 06th, 2024.
Stifel gave a rating of “Buy” to LXEO, setting the target price at $20 in the report published on November 28th of the previous year.
LXEO Trading at -6.14% from the 50-Day Moving Average
After a stumble in the market that brought LXEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.21% of loss for the given period.
Volatility was left at 8.43%, however, over the last 30 days, the volatility rate increased by 11.76%, as shares sank -17.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.35% upper at present.
During the last 5 trading sessions, LXEO fell by -16.89%, in comparison to the 20-day moving average, which settled at $16.62. In addition, Lexeo Therapeutics Inc. saw 4.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXEO starting from Townsend Richard Nolan, who sale 5,000 shares at the price of $17.65 back on Jun 10 ’24. After this action, Townsend Richard Nolan now owns 170,695 shares of Lexeo Therapeutics Inc., valued at $88,264 using the latest closing price.
Townsend Richard Nolan, the Chief Executive Officer of Lexeo Therapeutics Inc., sale 5,000 shares at $13.22 during a trade that took place back on May 13 ’24, which means that Townsend Richard Nolan is holding 170,695 shares at $66,093 based on the most recent closing price.
Stock Fundamentals for LXEO
The total capital return value is set at -0.38. Equity return is now at value -58.63, with -47.71 for asset returns.
Based on Lexeo Therapeutics Inc. (LXEO), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -4.98. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -377.67.
Currently, EBITDA for the company is -58.04 million with net debt to EBITDA at 2.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.16.
Conclusion
In summary, Lexeo Therapeutics Inc. (LXEO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
